CUTIA-B: CU-40102 (topical finasteride spray) has been approved for listing by the Hong Kong Department of Health
CUTIA-B announced that its CU-40102 (topical finasteride spray) has received marketing approval from the Hong Kong Department of Health, indicated for the treatment of androgenetic alopecia. This is another advancement for CU-40102 following its approval by the National Medical Products Administration of China. The topical formulation of CU-40102 allows patients to apply it directly, reducing systemic drug exposure, and is expected to be more readily accepted by patients. The launch of this product will expand market space and benefit more patients
According to the Zhitong Finance APP, CUTIA-B (02487) announced that the group's CU-40102 (topical finasteride spray) has received marketing approval from the Department of Health of the Government of the Hong Kong Special Administrative Region of the People's Republic of China, with the approved indication for the treatment of androgenetic alopecia. This is another significant progress for CU-40102 following its marketing approval from the National Medical Products Administration of China.
Finasteride, as a specific type II 5α-reductase competitive inhibitor, inhibits the conversion of testosterone to dihydrotestosterone in the scalp, which can treat androgenetic alopecia. Unlike oral finasteride, the topical formulation of CU-40102 allows patients to apply the medication directly and accurately to the surface of the scalp, reducing systemic exposure compared to oral medication. The group believes that CU-40102 as a topical medication will be more easily accepted by patients, providing an alternative solution for patients with androgenetic alopecia and becoming a new medication option for them.
As an important product for the group that has received marketing approval in the field of hair diseases and care, CU-40102 is undergoing extensive commercialization preparations in China. This approval will further deepen the international layout of CU-40102, expand its market space, and benefit more patients with androgenetic alopecia
